---
layout: default
title: Lincomycin Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 207
evidence_level: L5
indication_count: 0
---

# Lincomycin Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lincomycin Hydrochloride: Drug Repurposing Evaluation Report — Insufficient Prediction Data

---

## One-Sentence Summary

Lincomycin Hydrochloride is a lincosamide antibiotic, historically used to treat serious infections caused by susceptible Gram-positive organisms including streptococci, staphylococci, and pneumococci.
The TxGNN model **did not return any predicted repurposing indications** for this compound in the current evidence pack — no drug repurposing evaluation can be completed at this stage.
This report documents the current data gaps and outlines the steps required before a meaningful evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Serious Gram-positive bacterial infections (antibiotic class knowledge) |
| Predicted New Indication | — Not available (no TxGNN output) |
| TxGNN Prediction Score | — Not available |
| Evidence Level | — Not assessable |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | **Hold** |

---

## Why Evaluation Cannot Proceed

The core prerequisite for a repurposing evaluation — a TxGNN prediction — is absent in this evidence pack (`predicted_indications: []`). Two possible causes exist:

1. **The prediction pipeline has not yet been executed** for this compound. Lincomycin Hydrochloride may not have been matched to a DrugBank node (DrugBank ID is currently null), which would prevent the knowledge-graph model from scoring candidate disease associations.

2. **The model returned no candidates above the confidence threshold**, which itself may reflect insufficient graph connectivity due to the missing DrugBank mapping.

Additionally, the approved indication texts across all 20 Malaysian registrations were not captured in the data extraction step, meaning neither the drug's baseline therapeutic role nor its known safety profile can be confirmed from the structured data alone.

Without a target indication, the following sections — *Clinical Trial Evidence*, *Literature Evidence*, and *Why is This Prediction Reasonable?* — cannot be meaningfully populated and are omitted per reporting rules.

---

## Malaysia Market Information

Lincomycin Hydrochloride holds **20 product registrations** with the Malaysian drug authority (NPRA) and is confirmed as currently marketed. However, the structured licence details (product names, dosage forms, and approved indication texts) were not retrieved in this data extraction cycle — all licence record fields returned as empty. The individual registration table cannot be presented without this data.

> **Action required**: Re-query the NPRA product database to retrieve licence numbers, product names, dosage forms, and approved indication texts for all 20 registrations.

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> No key warnings, contraindications, or drug interaction data were captured in this evidence pack. NPRA/TFDA package insert PDFs should be retrieved and parsed before any clinical or regulatory review is conducted.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack for Lincomycin Hydrochloride is structurally incomplete — no TxGNN repurposing prediction is present, the DrugBank linkage is missing, and all structured regulatory detail fields are empty. There is currently no indication to evaluate and no safety baseline to assess against.

**To proceed, the following is needed:**

- **[Blocking]** Resolve the DrugBank ID mapping for Lincomycin Hydrochloride (search `DB01190` — the known DrugBank entry for lincomycin) to enable knowledge-graph scoring and unlock TxGNN prediction output.
- **[Blocking]** Re-run the NPRA product database query to populate licence numbers, product names, dosage forms, and approved indication texts for all 20 registrations.
- **[Blocking]** Download and parse the NPRA/TFDA package insert PDF to extract key warnings and contraindications — required before any safety screening step (currently marked as a Severity: Blocking data gap).
- **[High]** Populate the mechanism of action (MOA) field by querying the DrugBank API once the DrugBank ID is confirmed — Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, but this must be sourced from structured data rather than background knowledge.
- **[Pipeline]** After the above gaps are resolved, re-run the full TxGNN prediction pipeline (KG + DL + mapping steps) and regenerate the evidence pack to obtain `predicted_indications` before initiating a full repurposing evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

